U.S. Markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.0235%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • Vix

    17.20
    -0.49 (-2.77%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.0977%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.3587%)
     
  • BTC-USD

    34,728.03
    +925.09 (+2.74%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

BioNTech shots have stronger antibody response than Sinovac, Hong Kong study shows - SCMP

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

June 19 (Reuters) - People who are vaccinated against COVID-19 with BioNTech's vaccine were found to have "substantially higher" levels of antibodies than those who received Sinovac's jab, the South China Morning Post reported https://bit.ly/3iX7S5t on Saturday, citing a Hong Kong study.

Some who received the Sinovac vaccine might need a third booster shot as well, the newspaper said, citing lead researcher Professor Benjamin Cowling, an epidemiologist with the University of Hong Kong (HKU).

The government-commissioned study was conducted by HKU's school of public health and involved tracking the antibody responses of 1,000 people who received either vaccine, the report added.

Earlier this week, officials in Indonesia warned that more than 350 medical workers have caught COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, raising concerns about its efficacy against more infectious variants of the virus.

Earlier in June, Uruguay released real-world data on the impact of Sinovac Biotech's COVID-19 vaccine among its population that showed it was over 90% effective in preventing intensive care admissions and deaths.

The Uruguay government also studied the effectiveness of the Pfizer/BioNTech's vaccine among 162,047 health workers and people over 80 years old, and said the shot was 94% effective at preventing intensive care unit admissions and deaths, and reduced infections by 78%. (Reporting by Nandakumar D in Bengaluru; Editing by Raju Gopalakrishnan)